The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Zendog. My understanding from Avacta communications is that their Zika LFD was rxactky as you described. The covid one looked like it was similar but at some point they changed to AB first part of it. Presumably this either improved the test, made it more consistent or cheaper. The fact the AB is not suitable for Omnicron is not end of the world and I believe the test will be adapted. Avacta didn't give a timeline - probably because unlike monkey boy and his lordship they are not sure. They hadn't finished regulation so either we start again ( testing etc) or at least go to back of Q. Hence the sentiment turning.
LFD testing for covid is a commodity market. Indeed some manufacturers have avoided due to low margins. Would have been nice but not end of world. At some point they will make a working test, get it approved and sell some. However, all put into the shade by multiple Tx opportunities.
Touk, what made you choose your "Toukankahmoon" ID tag?
Looks like peeps are coming round to the timescale I guessed at a couple of weeks ago. Basically after new product produced and TT completed to produce a batch for clinical trials and product authorised fo UK use, we’ll be very lucky to get a couple of weeks sales revenue at end of March. By which time the next variant will be rampant.
Forget about LFDs our money will come from AVA6000 et al.
GLA
Clip clop clip clop - just back from McDs with another set of imaginary dates?
I would guess that travel light doesn't give a f*** he's not invested and here to deramp and try to be funny (if possible) by impersonating Rorkes Drift
Best question in a long time.
I wish I knew.
I think many are wishing that Avacta would say why.
Can we guess ? The antibody used to attach the colour but, which then makes the t-line visible when same protein grabbed by Affimers (which sticks to t-line). Happy to be corrected if I got that wrong.
Maybe issue with getting colour but to stick to affimer?
Maybe it’s a size thing(cos there is a difference, maybe antibody slows the s protein down). But I’d put your money in number 4 at Chepstow before using my thought on why as investment advice.
Travellight and all
Forgive me I've missed some messages on this BB that have covered this question already but, isn't it possible for Avacta to find a way of making the LFT work such that the whole functionality is governed by Affimers or, at least reagents that are under Avacta control? If not, why not? (If it is possible, it begs the question why haven't they done it already? Maybe that points to it not being possible? [if you assume Aacta are wholly switched on and competent])
Lol, look whose turned up as I was writing, Lord “it’s a two week job max”.
You don’t need to be an expert on biscuits to know that if a open 3 packets of rich tea and they each contain 30 biscuits, to make a guess that the forth packet is likely to be the same. A degree and 20 years experience in baked wheat based nutrition is not required(say hi to his Lordship, do you cut and paste what he sends or rewrite from scratch).
Marik you keep making statements that producing a new test is easy but every time anyone cast doubt on this you get defensive and claim they can’t possibly be right because it conflicts with your view.
can an antibody binding with a spike protein interfer with an affimer which would otherwise bind with that protein. What challenges do you think need to be overcome to get the new test out?
If it is this easy why are Abbot etc not licensing Affimers and making LFDs. I presume they too have experts? Seriously if it easy to make a test then why is licensing Affimers for LFD so bloody hard.
Give us a date, when do you think it will go back on sale. As an expert you use have some idea.
I’ll make a prediction. You will ignore every question above and again say “don’t listen to him, listen to me “ .
omg - from the original Pharmboy Google wannabe. Couldn't make this shlt up
Pot meet kettle.
I'm happy when someone raises an issue but admits they are not an expert. Through "xspirts" however....
From everything the monkey boy posts, between rounds of digestives, I conclude that he has access to Google but a very limited understanding of pharma industry in the real world. I'm going to take a stab at a contract sales rep and not a very good one. I wouldn't trust anything he says further then I'd place a special hobknob for him.
He is positive about Avacta - many on here are despite what has happened. There is no need to make stuff up - Avacta have multiple but high risk shots on goal. Live with it rather than generate the same nonsensense and then reply to yourself when none else gives a **** about what you say. Record so far is 9 posts on reply to yourself. Weird
What I like is that those with an opinion on a subject without any expertise can, on bulletin board like this, provide a narrative that places a nice hue on the subject.
antibodies are quite large molecules. Could a new antibody block the affimer from binding, does the structure of the spike protein change at binding of either the affimer or antibody, does that affect the other. Is the chemical environment eg pH etc the same for both to act optimally. Is one antibody less sensitive than another and does that make it a more robust if less specific choice(affimer job). Do all antibodies cost the same.
Are all suppliers equally as good. Will authorities want a whole new data set with the new test, or can it just be rolled out with a smile ? How fast to get those answers ?
I think we have agreed I am not an expert and I don't have a reasonable insight into what is involved other than it took a long time last time they did this:) TT for abingdon seemed to be a fairly long process or is my memory playing tricks on me?
loving the cheer leading thou Rar rar rar.
On a roll son ,keep it up .
As anyone with a reasonable understanding of molecular, will point out that the process of replacing the antibody is very straight forward. This is the bread and butter for Abingdon - they know what they are doing and have decades of experience.
https://www.trinitydelta.org/wp-content/uploads/2022/01/AVCT-Lighthouse-220110.pdf
"Avacta will work on replacing the antibody within the test to ensure that test performance with the Omicron variant is comparable to that demonstrated with other mutations."